DLBCL
From the Journals
Do Patients Benefit from Cancer Trial Participation?
Researchers conduct a meta-analysis comprising 141 comparisons of an investigational drug and a control treatment, which include immunotherapies...
Feature
Do Health-Related Social Needs Raise Mortality Risk in Cancer Survivors?
Researchers examine links between mortality risk and health-related social needs in patients who had cancer.
From the Journals
Terminal Cancer: What Matters to Patients and Caregivers
Patients and caregivers are less aligned on decisions about cost containment than end-of-life goals.
Feature
The Long, Controversial Search for a ‘Cancer Microbiome’
Research raised as many questions as answers about what we do and don’t know about microbiota and cancer.
From the Journals
Few Cancer Survivors Meet ACS Nutrition, Exercise Guidelines
Researchers estimate more than 9,000 survivors’ adherence to weight, physical activity, fruit and vegetable consumption, and alcohol intake...
Conference Coverage
Genetic Signatures May Predict CAR T Responders
Research data suggest that key genetic clues of patients with LBCL could show which are more — or less — likely to respond to axi-cel CAR T.
Conference Coverage
Tiny Doses of Metabolically Armed CAR T Show Benefits
The IL-10-expressing Meta10-19 CAR T-cell therapy improved outcomes in B-ALL and DLBCL at doses 5% and lower of standard CAR T products.
From the Journals
Most Targeted Cancer Drugs Lack Substantial Clinical Benefit
Researchers assess validity of the molecular targets and clinical benefits of genome-targeted cancer drugs approved in the United States from 2015...
Conference Coverage
No Routine Cancer Screening Option? New MCED Tests May Help
CanScan, MERCURY, and OncoSeek can detect a range of cancers and recognize the tissue of origin with high accuracy.
From the Journals
Oncologists Voice Ethical Concerns Over AI in Cancer Care
Researchers ask 204 oncologists from 37 states for their views on the ethical implications of using AI for cancer care.
From the Journals
Less Than 50% of Accelerated Approvals Show Clinical Benefit
Researchers review 46 cancer drugs granted accelerated approvals between 2013 and 2017.